OOIR: Observatory of International Research

Papers

(The median citation count of Journal of Pharmacokinetics and Pharmacodynamics is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Circadian rhythms: influence on physiology, pharmacology, and therapeutic interventions	63
Two heads are better than one: current landscape of integrating QSP and machine learning	32
Fast screening of covariates in population models empowered by machine learning	31
Recent applications of quantitative systems pharmacology and machine learning models across diseases	31
A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration	29
Population pharmacokinetic model selection assisted by machine learning	25
Lumbar cerebrospinal fluid-to-brain extracellular fluid surrogacy is context-specific: insights from LeiCNS-PK3.0 simulations	25
Optimum multi-drug regime for compartment model of tumour: cell-cycle-specific dynamics in the presence of resistance	20
Development of a genetic algorithm and NONMEM workbench for automating and improving population pharmacokinetic/pharmacodynamic model selection	19
Minimal brain PBPK model to support the preclinical and clinical development of antibody therapeutics for CNS diseases	16
Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies	16
Review of applications and challenges of quantitative systems pharmacology modeling and machine learning for heart failure	12
A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development	12
Generative adversarial networks for construction of virtual populations of mechanistic models: simulations to study Omecamtiv Mecarbil action	11
Two-pore physiologically based pharmacokinetic model validation using whole-body biodistribution of trastuzumab and different-size fragments in mice	10
Population pharmacokinetic modeling of intramuscular and oral dexamethasone and betamethasone in Indian women	9
What should patients do if they miss a dose of medication? A theoretical approach	8
Application of machine learning based methods in exposure–response analysis	8
Towards a translational physiologically-based pharmacokinetic (PBPK) model for receptor-mediated transcytosis of anti-transferrin receptor monoclonal antibodies in the central nervous system	8
Wide size dispersion and use of body composition and maturation improves the reliability of allometric exponent estimates	8
Machine learning-guided, big data-enabled, biomarker-based systems pharmacology: modeling the stochasticity of natural history and disease progression	8
Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates	8
Reduction of quantitative systems pharmacology models using artificial neural networks	8
Mathematical modeling of mammalian circadian clocks affecting drug and disease responses	7
The rhythm of a preterm neonate’s life: ultradian oscillations of heart rate, body temperature and sleep cycles	7

Physiologically-based pharmacokinetic model for 2,4-dinitrophenol	7
Applications of cosinor rhythmometry in pharmacology	7
A quantitative systems pharmacology model of plasma potassium regulation by the kidney and aldosterone	7
Prediction of CYP-mediated silybin A-losartan pharmacokinetic interactions using physiological based pharmacokinetic modeling	6
A pharmacokinetic and pharmacodynamic analysis of drug forgiveness	6
The Finite Absorption Time (FAT) concept en route to PBPK modeling and pharmacometrics	6
A Bayesian population physiologically based pharmacokinetic absorption modeling approach to support generic drug development: application to bupropion hydrochloride oral dosage forms	6
Optimal control for colistin dosage selection	6
The future of rare disease drug development: the rare disease cures accelerator data analytics platform (RDCA-DAP)	6
Development of PBPK model for intra-articular injection in human: methotrexate solution and rheumatoid arthritis case study	6
Low-dimensional neural ODEs and their application in pharmacokinetics	6
Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate	6
Population pharmacodynamic modeling of intramuscular and oral dexamethasone and betamethasone effects on six biomarkers with circadian complexities in Indian women	6
Application of different approaches to generate virtual patient populations for the quantitative systems pharmacology model of erythropoiesis	6
Towards a comprehensive assessment of QSP models: what would it take?	5
Development of minimal physiologically-based pharmacokinetic-pharmacodynamic models for characterizing cellular kinetics of CAR T cells following local deliveries in mice	5
Constant infusion case of one compartment pharmacokinetic model with simultaneous first-order and Michaelis–Menten elimination: analytical solution and drug exposure formula	5
Pharmacodynamic model of slow reversible binding and its applications in pharmacokinetic/pharmacodynamic modeling: review and tutorial	5
An integrated modelling approach for targeted degradation: insights on optimization, data requirements and PKPD predictions from semi- or fully-mechanistic models and exact steady state solutions	5
A semi-mechanistic exposure–response model to assess the effects of verinurad, a potent URAT1 inhibitor, on serum and urine uric acid in patients with hyperuricemia-associated diseases	5
Evaluation of prompt engineering strategies for pharmacokinetic data analysis with the ChatGPT large language model	5
PK/PD modeling of a clazosentan thorough QT study with hysteresis in concentration-QT and RR-QT	5
Generation and application of avatars in pharmacometric modelling	5
Mechanistic incorporation of FcRn binding in plasma and endosomes in a whole body PBPK model for large molecules	5
Accelerating robust plausible virtual patient cohort generation by substituting ODE simulations with parameter space mapping	5
An industry perspective on current QSP trends in drug development	5
Training the next generation of pharmacometric modelers: a multisector perspective	5
Delay differential equations based models in NONMEM	5
From data to QSP models: a pipeline for using Boolean networks for hypothesis inference and dynamic model building	5
Statistical analysis of one-compartment pharmacokinetic models with drug adherence	4
Towards a platform quantitative systems pharmacology (QSP) model for preclinical to clinical translation of antibody drug conjugates (ADCs)	4
Variability and uncertainty: interpretation and usage of pharmacometric simulations and intervals	4
A quantitative systems pharmacology model of hyporesponsiveness to erythropoietin in rats	4
Operational characteristics of full random effects modelling (‘frem’) compared to stepwise covariate modelling (‘scm’)	4
PBPK model for antibody disposition in mouse brain: validation using large-pore microdialysis data	4
A next generation mathematical model for the in vitro to clinical translation of T-cell engagers	4
Two compartmental fractional derivative model with general fractional derivative	4
Comparison of sequential and joint nonlinear mixed effects modeling of tumor kinetics and survival following Durvalumab treatment in patients with metastatic urothelial carcinoma	4
Understanding virtual patients efficiently and rigorously by combining machine learning with dynamical modelling	4
Estimating drug potency in the competitive target mediated drug disposition (TMDD) system when the endogenous ligand is included.	4
Semi-empirical anticoagulation model (SAM): INR monitoring during Warfarin therapy	3
Should patients skip late doses of medication? A pharmacokinetic perspective	3
Modeling the acute effects of exercise on glucose dynamics in healthy nondiabetic subjects	3
How circadian variability of the heart rate and plasma electrolytes concentration influence the cardiac electrophysiology – model-based case study	3
Computing optimal drug dosing with OptiDose: implementation in NONMEM	3
Explaining in-vitro to in-vivo efficacy correlations in oncology pre-clinical development via a semi-mechanistic mathematical model	3
Pathway-level analysis of genome-wide circadian dynamics in diverse tissues in rat and mouse	3
A quantitative systems pharmacology model for simulating OFF-Time in augmentation trials for Parkinson’s disease: application to preladenant	3
Physiologically based pharmacokinetic model to predict drug–drug interactions with the antibody–drug conjugate enfortumab vedotin	3
R-praziquantel integrated population pharmacokinetics in preschool- and school-aged African children infected with Schistosoma mansoni and S. haematobium and Lao adults infected with Opisthorchis vive	3

Modeling of levothyroxine in newborns and infants with congenital hypothyroidism: challenges and opportunities of a rare disease multi-center study	3
Thoughts on plagiarism and the case against Claudine Gay	3
Rare oncology therapeutics: review of clinical pharmacology package of drug approvals (2019–2023) by US FDA, best practices and recommendations	3
Clinical validation of translational antibody PBPK model using tissue distribution data generated with 89Zr-immuno-PET imaging	3
Population pharmacokinetic and pharmacokinetic-pharmacodynamic modeling of bempedoic acid and low-density lipoprotein cholesterol in healthy subjects and patients with dyslipidemia	3
From complex data to biological insight: ‘DEKER’ feature selection and network inference	3
Knowledge dissemination and central indexing of resources in pharmacometrics: an ISOP education working group initiative	3
Concentration–QTc analysis for single arm studies	3
Experimental and computational assessment of the synergistic pharmacodynamic drug–drug interactions of a triple combination therapy in refractory HER2-positive breast cancer cells	3
Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials	3
Comparing the performance of first-order conditional estimation (FOCE) and different expectation–maximization (EM) methods in NONMEM: real data experience with complex nonlinear parent-metabolite phar	2
Generative models for age, race/ethnicity, and disease state dependence of physiological determinants of drug dosing	2
A latent variable approach to account for correlated inputs in global sensitivity analysis	2
Optimal sample selection applied to information rich, dense data	2
Current practices for QSP model assessment: an IQ consortium survey	2
A pharmacodynamic model of tidal volume and inspiratory sevoflurane concentration in children during spontaneous breathing	2
Achieving big with small: quantitative clinical pharmacology tools for drug development in pediatric rare diseases	2
A minimal physiologically based pharmacokinetic model to study the combined effect of antibody size, charge, and binding affinity to FcRn/antigen on antibody pharmacokinetics	2
Exposure-response modeling improves selection of radiation and radiosensitizer combinations	2
A proof of concept reinforcement learning based tool for non parametric population pharmacokinetics workflow optimization	2
A longitudinal model for the Mayo Clinical Score and its sub-components in patients with ulcerative colitis	2
Inferring pulmonary exposure based on clinical PK data: accuracy and precision of model-based deconvolution methods	2
A quantitative systems pharmacological approach identified activation of JNK signaling pathway as a promising treatment strategy for refractory HER2 positive breast cancer	2
Semi-mechanistic modeling of resistance development to β-lactam and β-lactamase-inhibitor combinations	2
Estimation of time to progression and post progression survival using joint modeling of summary level OS and PFS data with an ordinary differential equation model	2
External control arms for rare diseases: building a body of supporting evidence	2
A system pharmacology Boolean network model for the TLR4-mediated inflammatory response in early sepsis	2
Impact of model misspecification on model-based tests in PK studies with parallel design: real case and simulation studies	2
Employing zero-inflated beta distribution in an exposure-response analysis of TYK2/JAK1 inhibitor brepocitinib in patients with plaque psoriasis	2
Learning pharmacometric covariate model structures with symbolic regression networks	2
Analysis of cellular kinetic models suggest that physiologically based model parameters may be inherently, practically unidentifiable	2
Improved numerical stability for the bounded integer model	1
On inductive biases for the robust and interpretable prediction of drug concentrations using deep compartment models	1
Systemic exposure following intravitreal administration of therapeutic agents: an integrated pharmacokinetic approach. 1. THR-149	1
Latent variable indirect response modeling of clinical efficacy endpoints with combination therapy: application to guselkumab and golimumab in patients with ulcerative colitis	1
Population pharmacokinetic modeling and dosing simulation of avalglucosidase alfa for selecting alternative dosing regimen in pediatric patients with late-onset pompe disease	1
Characterization of anti-drug antibody dynamics using a bivariate mixed hidden-markov model by nonlinear-mixed effects approach	1
Go beyond the limits of genetic algorithm in daily covariate selection practice	1
Pharmacometric estimation methods for aggregate data, including data simulated from other pharmacometric models	1
Challenges, approaches and enablers: effectively triangulating towards dose selection in pediatric rare diseases	1
Visual predictive check of longitudinal models and dropout	1
Physiologically-based pharmacokinetic model for pulmonary disposition of protein therapeutics in humans	1
A population K-PD model analysis of long-term testosterone inhibition in prostate cancer patients undergoing intermittent androgen deprivation therapy	1
Assessing the performance of QSP models: biology as the driver for validation	1
Improving categorical endpoint longitudinal exposure–response modeling through the joint modeling with a related endpoint	1
Population pharmacokinetics of the dual endothelin receptor antagonist aprocitentan in subjects with or without essential or resistant hypertension	1
International society of Pharmacometrics Mentorship Program (IMP): feedback survey from the first cohort of mentor-mentee pairs	1
Evaluation of ChatGPT and Gemini large language models for pharmacometrics with NONMEM	1
Pharmacometric model of agalsidase–migalastat interaction in human: a novel mechanistic model of drug-drug interaction between a therapeutic protein and a small molecule	1
Linking categorical models for prediction of pleasantness score using individual predictions of sweetness and creaminess: An advancement of categorical modeling	1
Comparison of monoclonal antibody disposition predictions using different physiologically based pharmacokinetic modelling platforms	1
Improving priors for human monoclonal antibody linear pharmacokinetic parameters by using half-lives from non-human primates	1
A two-stages global sensitivity analysis by using the δ sensitivity index in presence of correlated inputs: application on a tumor growth inhibition model based on the dynamic energy budget theory	1
Likelihood comparisons in bounded outcome score analysis must be internally consistent	1
Target-mediated drug disposition model for drugs with N > 2 binding sites that bind to a target with one binding site	1
A comparison of covariate selection techniques applied to pre-exposure prophylaxis (PrEP) drug concentration data in men and transgender women at risk for HIV	1
Pharmacometric modeling of drug adverse effects: an application of mixture models in schizophrenia spectrum disorder patients treated with clozapine	1
How drug onset rate and duration of action affect drug forgiveness	1
Do epoch lengths of hypnotic depth indicators affect estimated of blood-brain equilibration rate constants of propofol?	1
Computational neurosciences and quantitative systems pharmacology: a powerful combination for supporting drug development in neurodegenerative diseases	1
Mechanistic inference of the metabolic rates underlying $$^{13}$$C breath test curves	1
Global sensitivity analysis in physiologically-based pharmacokinetic/pharmacodynamic models of inhaled and opioids anesthetics and its application to generate virtual populations	1
Oral docetaxel plus encequidar – A pharmacokinetic model and evaluation against IV docetaxel	1
Joint longitudinal model-based meta-analysis of FEV1 and exacerbation rate in randomized COPD trials	1
Individualized optimization of colistin loading doses	1